SUPPORTIVE CARE IN CANCER

Response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial

Cindy Weinstein · Karin Jordan · Stuart A. Green · Elber Camacho · Saleem Khanani · Elizabeth Beckford-Brathwaite · Annpey Pong · Stephen J. Noga · Bernardo L. Rapoport

Corresponding author: Dr. Cindy Weinstein, Merck Research Laboratories, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, NJ 07065, USA. Tel: 1-732-594-6106; e-mail: cindy.l.weinstein@merck.com.

Online Resource 4 Complete response (CR) by chemotherapy type, chemotherapy duration, and tumor type in the delayed phase

	Single day		Multiple days	
Tumor type	Carbo (CR)	Non-carbo (CR)	Carbo (CR)	Non-carbo (CR)
Breast	44 (25)	166 (124)	0	0
Colorectal	0	28 (21)	1 (1)	163 (130)
Gynecologic	142 (89)	8 (6)	0	2 (2)
Lung	217 (162)	0	32 (31)	0

Other	74 (56)	27 (21)	2 (1)	58 (38)

Carbo carboplatin